3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
40
Pancreatic Neoplasms
17
Breast Neoplasms
17
Esophageal Neoplasms
14
Neoplasms
13
Stomach Neoplasms
12
Lung Neoplasms
12
Triple Negative Breast Neoplasms
11
Rectal Neoplasms
11
Neoplasm Metastasis
11
Esophageal Squamous Cell Carcinoma
11
Uterine Cervical Neoplasms
10
Colorectal Neoplasms
10
Small Cell Lung Carcinoma
9
Ovarian Neoplasms
9
Head and Neck Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Nasopharyngeal Carcinoma
5
Leukemia, Myeloid, Acute
5
Endometrial Neoplasms
5
Recurrence
4
NSCLC
4
Mouth Neoplasms
4
Colonic Neoplasms
4
Lymphoma
3
Glioma
3
Cholangiocarcinoma
3
Adenocarcinoma Of Esophagus
3
Urinary Bladder Neoplasms
2
Interventions
pembrolizumab
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
cemiplimab
2
camrelizumab
2
cabozantinib
2
apatinib
2
Mitotane
2
fludarabine phosphate
1
dostarlimab
1
Megestrol Acetate
1
Interleukin-13
1
Fluorodeoxyglucose F18
1
Floxuridine
1
Etoposide
1
Drug Therapy
1
Doxorubicin
1
Dexamethasone
1
Cyclophosphamide
1
Cisplatin
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Adrenocortical Carcinoma
×
Drug Therapy
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled